By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


New once-daily inhaler for COPD and asthma

The first once-daily inhaled corticosteroid/long acting beta2-agonist combination has been launched in the UK for treating asthma and chronic obstructive pulmonary disease.

Fluticasone furoate/vilanterol (Relvar Ellipta) is the first ICS/LABA to launch with both an asthma and COPD indication at the same time.

Two strengths have been approved for the treatment of asthma (92/22 mcg and 184/22 mcg) and one strength has been approved for COPD (92/22 mcg).

All strengths are administered once-daily using the Ellipta, a new dry powder inhaler, according to manufacturer GlaxoSmithKline.

It said ease-of-use handling studies had shown that over 95% of asthma and COPD patients used the Ellipta inhaler device correctly for the first time.

The product is priced at £27.80 (92/22mcg) and £38.87 (184/22mcg).


Are you able to Speak out Safely?

Sign our petition to put pressure on your trust to support an open and transparent NHS

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!